来自Science的科研成果
来自中外制药株式会社转化研究部等机构的科学家们通过对食蟹猴样本注射研制的抗体成功减少了结节性病变的体积、改善了纤维化和粘连，此研究强调了IL-8在子宫内膜异位症中的作用，表明移植IL-8可能具有疾病改善作用。未来子宫内膜异位症或有
望治愈。
Abstract
Current pharmacological treatments for endometriosis are limited to hormonal agents that can relieve pain but cannot cure the disease. Therefore, the development of a disease-modifying drug for endometriosis is an unmet medical need. By studying human endometriotic samples, we found that the progression of endometriosis was associated with the development of inflammation and fibrosis. In addition, IL-8 expression was highly up-regulated in endometriotic tissues and closely correlated with disease progression. We created a long-acting recycling antibody against IL-8 (AMY109) and evaluated its clinical potency. Because rodents do not produce IL-8 and do not experience menstruation, we analyzed the lesions in cynomolgus monkeys that spontaneously developed endometriosis and in a surgically induced endometriosis monkey model. Both spontaneously developed and surgically induced endometriotic lesions demonstrated pathophysiology that was highly similar to that of human endometriosis. Once-a-month subcutaneous injection of AMY109 to monkeys with surgically induced endometriosis reduced the volume of nodular lesions, lowered the Revised American Society for Reproductive Medicine score as modified for monkeys, and ameliorated fibrosis and adhesions. In addition, experiments using cells derived from human endometriosis revealed that AMY109 inhibited the recruitment of neutrophils to endometriotic lesions and the production of monocyte chemoattractant protein-1 from neutrophils. Thus, AMY109 may represent a disease-modifying therapy for patients with endometriosis.
研究发现：
目前对子宫内膜异位症的药物治疗仅限于激素药物，这些药物可以缓解疼痛，但不能治愈疾病。因此，开发一种治疗子宫内膜异位症的药物是一个尚未满足的医学需求。通过研究人类子宫内膜异位症样本，我们发现子宫内膜异位症的进展与炎症和纤维化的发展有关。此外，IL-8的表达在子宫内膜异位症组织中高度上调，与疾病进展密切相关。我们制备了一种长效的针对IL-8的循环抗体(AMY109)，并评估了其临床效力。由于啮齿动物不产生IL-8，也没有月经，我们分析了自发发生子宫内膜异位症的食蟹猴和手术诱导的子宫内膜异位症猴模型的病变。自发发展和手术诱导的子宫内膜异位症病变表现出与人类子宫内膜异位症高度相似的病理生理学。对手术诱发子宫内膜异位症的猴子每月一次皮下注射AMY109可减少结节性病变的体积，降低经修订的美国生殖医学学会(American Society for Reproductive Medicine)对食蟹猴子的评分，改善纤维化和粘连。此外，利用来自人子宫内膜异位症的细胞进行的实验显示，AMY109抑制中性粒细胞向子宫内膜异位症病变的募集，以及中性粒细胞产生单核细胞趋化蛋白-1。因此，AMY109可能代表子宫内膜异位症患者的一种疾病改善疗法。
原文链接：https://www.science.org/doi/10.1126/scitranslmed.abq5858
通讯作者：
AyakoNishimoto-Kakiuchi,Izumi Sato,Kiyotaka Nakano,Hiroshi Ohmori,
Yoko Kayukawa,Hiromi Tanimura,Sachiya Yamamoto ,Yuichiro Sakamoto,Genki Nakamura,Atsuhiko Maeda,Kentaro Asanuma, Atsuhiko Kato,Tadashi Sankai,Ryo Konno,Hisafumi Yamada-Okabe
*文章仅做分享交流使用，版权原作者所有，侵删。
